Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

8.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

3.0K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
3.0K
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal01:22

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

2.8K
Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
2.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

4.9K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.9K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

552
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
552

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Autoimmune Hemolytic Anemia Following Intravenous Immunoglobulin in Kawasaki Disease.

Cureus·2026
Same author

Unmet HIV and STI Prevention Needs and Limited Linkage to Care Among Gay, Bisexual, and Other Men Who Have Sex with Men in Southern Spain: A Community-Based Intervention Study.

AIDS patient care and STDs·2026
Same author

Oligomerization enables the selective targeting of an intrinsically disordered region by a small molecule.

Science advances·2026
Same author

Apolipoprotein E-enriched protein corona enhances the blood-brain barrier transport of β-sheet-breaker peptide-functionalized gold nanoparticles.

Colloids and surfaces. B, Biointerfaces·2026
Same author

Equine Infectious Anemia Virus in Equids: A Large-Scale Serosurvey in Western Europe.

Animals : an open access journal from MDPI·2025
Same author

The Impact of Adult Cannabis Use Legalization in California: A Qualitative Review of Subject Matter Expert Opinions on Proposition 64.

Cannabis (Albuquerque, N.M.)·2025

Related Experiment Video

Updated: Mar 28, 2026

A Novel In Vitro Wound Healing Assay to Evaluate Cell Migration
08:55

A Novel In Vitro Wound Healing Assay to Evaluate Cell Migration

Published on: March 17, 2018

23.5K

Peptides Targeting EGF Block the EGF-EGFR Interaction.

Salvador Guardiola1, Mireia Díaz-Lobo1, Jesús Seco1

  • 1Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Baldiri Reixac 10, 08028, Barcelona, Spain.

Chembiochem : a European Journal of Chemical Biology
|December 18, 2015
PubMed
Summary

Novel peptides targeting epidermal growth factor (EGF) were designed to inhibit its interaction with the epidermal growth factor receptor (EGFR). This offers a new strategy for cancer therapy, potentially overcoming drug resistance.

Keywords:
SAWcancer therapymembrane receptorspeptidesprotein-protein interaction

More Related Videos

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
08:35

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles

Published on: January 4, 2012

28.8K
Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
15:05

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

9.5K

Related Experiment Videos

Last Updated: Mar 28, 2026

A Novel In Vitro Wound Healing Assay to Evaluate Cell Migration
08:55

A Novel In Vitro Wound Healing Assay to Evaluate Cell Migration

Published on: March 17, 2018

23.5K
Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
08:35

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles

Published on: January 4, 2012

28.8K
Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
15:05

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

9.5K

Area of Science:

  • Oncology
  • Drug Discovery
  • Molecular Biology

Background:

  • Epidermal growth factor receptor (EGFR) is a crucial target in cancer chemotherapy.
  • Drug resistance to current EGFR inhibitors leads to tumor relapse, necessitating alternative therapeutic strategies.

Purpose of the Study:

  • To design novel peptide inhibitors targeting the epidermal growth factor (EGF) ligand.
  • To evaluate the efficacy of these peptides in blocking EGF-EGFR interactions for potential cancer therapy.

Main Methods:

  • Peptide design using molecular docking and receptor hotspot mimicry.
  • Biophysical techniques for characterizing ligand-protein structure and interactions.
  • In vitro assays to assess the inhibition of EGF-EGFR binding.

Main Results:

  • Successfully designed peptides that bind to EGF.
  • Demonstrated the capacity of these peptides to inhibit EGF-EGFR interaction in vitro.
  • Identified a new class of binders targeting protein-protein interactions.

Conclusions:

  • A novel drug design strategy targeting protein-protein interactions was developed.
  • The designed peptides represent a new class of EGFR pathway inhibitors.
  • These compounds could serve as complementary agents in multidrug cancer therapy to overcome resistance.